T&TV59: A very important movement when “painting” the surface of stone for excellent dusting. 1st : Keep the perfect distance between stone’s surface & Laser Fiber (never touch it) & 2nd: ROTATE the scope with your left thumb & index finger (reproducing minimal torque mvt)

Progression on BCG to MIBC managed without NAC portends poor prognosis after RC. Treating these patients with contemporary NAC achieves similar survival as de novo BCa patients. Pres. this pm session PD51 #aua2021 Ashish M. Kamat, MD, MBBS Kelly Bree MD Anderson Cancer Center Eugene Lee

Relapse of pT0 Bladder Cancer Possible After Radical Cystectomy fal.cn/3khwW #SUO21 #blcsm Research team: @asalahaziz @khurshidguru Ahmed Aly  mani Roswell Park Genitourinary Oncology

2021 Best Scientific Paper on Clinical Research Treatment of High-grade NMIBC by Standard Number and Dose of BCG Instillations Vs Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology (EAU) Research Foundation Phase 3 RCT “NIMBUS” buff.ly/2ZJLzH5

PI-RR (Prostate Magnetic Resonance Imaging for Local Recurrence Reporting) is the ‘PI-RADS’ assessment for prostate cancer recurrence after wholke gland therapy (prostatectomy or radiotherapy). see: DOI: 10.1016/j.euo.2021.01.003

Current Issue: Open to Debate Cytoreductive Nephrectomy in 2021: Obsolete buff.ly/3nWuODQ Luis A. Meza Neal S. Chawla Gianluca Giannarini Sumanta K. Pal, MD, FASCO

Great technique for preventing lymphoceles after Plnd by Daniel D Eun MD Temple Urology Peritoneal interposition flaps - no lymphoceles in multiple studies! #NARUS2022 @NAmerRoboUrol

Prostate MRI in Stereotactic Body Radiation Treatment Planning and Delivery for Localized Prostate Cancer pubs.rsna.org/doi/10.1148/rg… 🔵A must read article for clinicians who are interested in localized #prostatecancer 👍Congrats to all Authors #CancerResearch #MedTwitter

Phenomenal milestone. Largest series of urological procedures on the Versius Robotic Surgical System SIUT Pakistan link.springer.com/article/10.100… Irfan Rizvi MD, FRCS(Eng), FACS, FASCRS CMR Surgical @khurshidGuru Per Vegard Nerseth Journal of Robotic Surgery Rehan Mohsin Harris H. Qureshi Ahmed Aly. #roboticsurgery #SIUT #ApnaHai

Can’t tweet about this study enough! TTh reduced DM rates. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomised, double-blind, placebo-controlled, 2-year, phase 3b trial - PubMed pubmed.ncbi.nlm.nih.gov/33338415/

I have essentially switched from IPSS to VPSS as initial screen.

doi.org/10.1016/j.euro…. - Expert-EAU group made enormous efforts for algorithm optimizing benefits vs harms in early PCa detection - Pre-MRI Risk Calculator avoids 41% of MRIs and 60% of biopsies at a cost of missing 5% csPCa - PSAD>.10 avoids 34% of MRI at a cost of 4% csPCa

كلما خبت همتي عدت إلى هذا المقطع..

Predicting the Need for Biopsy to Detect csPCa in Pts with MRI–detected PIRADS/Likert ≥3 Lesion: Development and Multinational External Validation of the Imperial Rapid Access to Prostate Imaging and Diagnosis Risk Score buff.ly/3PmIuCE Peters, Hashim U. Ahmed et al

Is MRI a game-changer to properly investigate urethral stenosis and plan the appropriate treatment? Or retrograde urethrography is enough? #UroSoMe

This strongly supports risk adapted early detection/screening: - PSA (when >3 ng/ml) followed by - risk calculator, when positive followed by - bi-parametric (quality controlled) MRI and MR-targeted biopsy.

Very nice analysis of Targeted Biopsy negative Prostate Lesions using #prostateMRI 🇬🇧🇫🇷🇺🇸 "Magnetic Resonance Imaging Follow-up of Targeted Biopsy-negative Prostate Lesions" sciencedirect.com/science/articl… #cancerresearch #medtwitter #teamscience

Our work about treatment decisions for localized prostate cancer Roswell Park Genitourinary Oncology Khurshid A. Guru

Why NOT call GS 3+3 benign: 1. 3+3 has same microsc., immunohistochem. & molecular features as >3+3 2. 3+3 can show pT3 & metas 3. 3+3 is often undergraded and undersampled 4. Due to interobserver variability 3+3 can turn into 3+4. This is difficult to explain to patient

1/2 I can’t help but feel that the reply from authors confirm our concerns about the generalizability of the Protect trial: 1) Protect represent community-based screening, which doesn’t happen in US practice, NEJM pubmed.ncbi.nlm.nih.gov/37407012/